Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Birch Pollen Allergy - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Birch Pollen Allergy - Pipeline Review, H2 2015', provides an overview of the Birch Pollen Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Birch Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Birch Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Birch Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Birch Pollen Allergy Overview 7 Therapeutics Development 8 Pipeline Products for Birch Pollen Allergy - Overview 8 Pipeline Products for Birch Pollen Allergy - Comparative Analysis 9 Birch Pollen Allergy - Therapeutics under Development by Companies 10 Birch Pollen Allergy - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Birch Pollen Allergy - Products under Development by Companies 14 Birch Pollen Allergy - Companies Involved in Therapeutics Development 15 ALK-Abello A/S 15 Allergopharma Joachim Ganzer KG 16 Anergis SA 17 Biomay AG 18 Circassia Pharmaceuticals Plc 19 HAL Allergy BV 20 Stallergenes S.A. 21 Birch Pollen Allergy - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 AllerT - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Birch-SPIRE - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 BM-31 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 PL-102 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 rBet v1 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 rBet v1-FV - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 STG-210 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Birch Pollen Allergy - Recent Pipeline Updates 39 Birch Pollen Allergy - Dormant Projects 41 Birch Pollen Allergy - Discontinued Products 42 Birch Pollen Allergy - Product Development Milestones 43 Featured News & Press Releases 43 Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial 43 Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen 43 Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting 43 Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT 44 Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT 44 May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen 45 Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT 46 Feb 27, 2014: Phase IIb Results of Anergis� Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego 46 Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT 46 Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
Number of Products under Development for Birch Pollen Allergy, H2 2015 8 Number of Products under Development for Birch Pollen Allergy - Comparative Analysis, H2 2015 9 Number of Products under Development by Companies, H2 2015 10 Comparative Analysis by Late Stage Development, H2 2015 11 Comparative Analysis by Clinical Stage Development, H2 2015 12 Comparative Analysis by Early Stage Development, H2 2015 13 Products under Development by Companies, H2 2015 14 Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2015 15 Birch Pollen Allergy - Pipeline by Allergopharma Joachim Ganzer KG, H2 2015 16 Birch Pollen Allergy - Pipeline by Anergis SA, H2 2015 17 Birch Pollen Allergy - Pipeline by Biomay AG, H2 2015 18 Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2015 19 Birch Pollen Allergy - Pipeline by HAL Allergy BV, H2 2015 20 Birch Pollen Allergy - Pipeline by Stallergenes S.A., H2 2015 21 Assessment by Monotherapy Products, H2 2015 22 Number of Products by Stage and Target, H2 2015 23 Number of Products by Stage and Route of Administration, H2 2015 25 Number of Products by Stage and Molecule Type, H2 2015 27 Birch Pollen Allergy Therapeutics - Recent Pipeline Updates, H2 2015 39 Birch Pollen Allergy - Dormant Projects, H2 2015 41 Birch Pollen Allergy - Discontinued Products, H2 2015 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
